In addition to demonstrating limited utility of 18F-DCFPyL PET/CT as a diagnostic tool in the staging of women with HGSOC, our findings also suggest that further exploration of PSMA as a target for a theranostic approach is unlikely to be productive in women with advanced ovarian cancers. This evidence concerns the gene FOLH1 and ovarian carcinoma.